Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elif Tama

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Diabetes, Obesity & Metabolism|March 12, 2024
The association between previous use of anti-obesity medication and semaglutide weight loss outcomesWissam Ghusn, Sima Fansa, Diego Anazco, et al.
Mayo Clinic Proceedings|November 27, 2024
Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or ObesityRene Rivera Gutierrez, Elif Tama, Dima Bechenati, et al.
Obesity Pillars|November 5, 2024
Efficacy of in-person versus digital enhanced lifestyle interventions in adults with overweight and obesityDiego Anazco, Maria A Espinosa, Lizeth Cifuentes, et al.
International Journal of Obesity (2005)|February 1, 2024
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered studyWissam Ghusn, Sima Fansa, Diego Anazco, et al.
Obesity (Silver Spring, Md.)|June 15, 2026
Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective AnalysisRegina Castaneda, Dima Bechenati, Rene de J Rivera Gutierrez, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Diabetes, Obesity & Metabolism|March 12, 2024
The association between previous use of anti-obesity medication and semaglutide weight loss outcomesWissam Ghusn, Sima Fansa, Diego Anazco, et al.
Mayo Clinic Proceedings|November 27, 2024
Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or ObesityRene Rivera Gutierrez, Elif Tama, Dima Bechenati, et al.
Obesity Pillars|November 5, 2024
Efficacy of in-person versus digital enhanced lifestyle interventions in adults with overweight and obesityDiego Anazco, Maria A Espinosa, Lizeth Cifuentes, et al.
International Journal of Obesity (2005)|February 1, 2024
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered studyWissam Ghusn, Sima Fansa, Diego Anazco, et al.
Obesity (Silver Spring, Md.)|June 15, 2026
Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective AnalysisRegina Castaneda, Dima Bechenati, Rene de J Rivera Gutierrez, et al.
Pageof 2